This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Recombinant Canine Phospholipase A2 Group VII (LpPLA2), N-His
Product Overview
BioVenic's Recombinant Canine Phospholipase A2 Group VII (LpPLA2), N-His is a recombinant protein expressed from E.coli expression system. Its predicted molecular weight is 49.1 kDa. The purity is>97% (SDS-PAGE). The endotoxin level is <1 EU/μg (LAL). It can be used as a positive control or as an immunogen.
Specifications
Target Information
Lipoprotein-associated phospholipase A2 (Lp-PLA2) plays a role in the mediation of vascular inflammation through the regulation of lipid metabolism in the bloodstream. As a result, this enzyme has been the subject of extensive research to identify its involvement in vascular inflammation-related diseases, with a particular focus on atherosclerosis.
Shipping and Storage
This product is shipped with dry ice. Avoid repeated freezing and thawing. Store for 4 weeks at 2-8°C, for 12 months at -80°C.
Documents
The product is for research use only.
Not for commercial, prophylactic, diagnostic, or therapeutic applications.
User Note
- Always centrifuge tubes before opening. Avoid mixing by vortexing or pipetting. Reconstitute in 10 mM PBS (pH 7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex. Aliquote the reconstituted solution to minimise freeze-thaw cycles.
References
- Huang, Fubao et al. "Lipoprotein-associated phospholipase A2: The story continues." Medicinal research reviews vol. 40,1 (2020): 79-134.